Coreline Soft and Optellum to Integrate AI Platforms for Lung Nodule Care

Integrating FDA-Approved Lung Nodule CADe with Risk Assessment and Patient Management Platform
From Nodule Detection to Risk Evaluation and Follow-Up Management: Advancing Global Collaboration

Coreline Soft is embarking on an AI partnership with Optellum, a US-based healthcare AI company, to support the entire clinical workflow for lung nodule diagnosis and management.

On August 19, both companies announced that they are working to connect Coreline Soft’s FDA-cleared lung nodule computer-aided detection (CADe) software, “AVIEW Lung Nodule CAD,” with Optellum’s AI-based chest care platform, “LungOS.”

CorelineSoft company logo image. CorelineSoft

Through this collaboration, Coreline Soft’s lung nodule detection capabilities will be linked with Optellum’s computer-aided diagnosis (CADx), risk stratification, and patient management features. The aim is to not only detect lung nodules in imaging, but also to assess their malignancy risk, prioritize patient care accordingly, and support a comprehensive follow-up and management workflow.

AVIEW Lung Nodule CAD is software designed to assist medical professionals in detecting lung nodules from chest CT scans. Optellum’s LungOS is a platform for identifying and managing patients with incidentally detected lung nodules, offering both risk assessment and patient management solutions.

After a lung nodule is found on imaging, its size, shape, and potential malignancy must be evaluated, and follow-up testing or observation determined according to risk. In the United States, approximately 20 million chest CT scans are performed each year, during which more than 1.6 million people are found to have incidentally detected lung nodules.

The two companies plan to build an integrated clinical workflow covering nodule detection, risk evaluation, patient prioritization, and follow-up management through this joint effort.

Jonathan Watkins, CEO of Optellum, stated, “Coreline Soft’s expertise in AI-powered lung nodule detection and Optellum’s capabilities in risk assessment and management for lung nodules are highly complementary. We will support lung nodule patients in receiving the appropriate care pathway.”

Jinkook Kim, CEO of Coreline Soft, commented, “Coreline Soft has continuously advanced AI technologies to support clinicians and multidisciplinary teams in lung cancer care. We will contribute to a more efficient and scalable lung cancer care model.”

Coreline Soft plans to leverage this collaboration to expand its chest AI business in North America and global markets, moving beyond single AI product supply toward deeper partnerships with local platforms and healthcare providers.

This content was produced with the assistance of AI translation services.